🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Invivyd announces board member resignation

Published 03/12/2024, 07:20 am
IVVD
-

Invivyd, Inc. (NASDAQ:IVVD), a biotechnology company specializing in biological products with a current market capitalization of $83.56 million, announced the immediate resignation of Sara Cotter from its Board of Directors and all committees thereof.

With a fiscal year ending on December 31, Invivyd continues its endeavors in the biotech industry under the state of Delaware's incorporation laws. The company has not released further comments on the matter.

In other recent news, Invivyd, Inc. reported steady growth in its third-quarter financial results, despite facing regulatory challenges. The company highlighted an 80% to 90% reduction in symptomatic COVID-19 risk with its antibody, pemivibart, and introduced a new antibody candidate, VYD2311, which began human studies in August 2024. Invivyd's Q3 net product revenue was $9.3 million, with an ending cash balance of $107 million.

The company is aiming for profitability by June 2025 through a strategic restructuring to enhance commercial outreach, primarily serving the immunocompromised community. Invivyd is also in discussions with the FDA regarding the regulatory pathway for VYD2311.

Despite concerns about pemivibart's efficacy against certain SARS-CoV-2 variants, Invivyd remains confident in its clinical data and regulatory pathway for its products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.